Pfizer (PFE) announced that it is voluntarily withdrawing all lots of Oxbryta for the treatment of sickle cell disease as data shows risks outweigh its overall benefits in the approved population. Barclays believes the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3989254/-Pfizer-withdrawal-of-Oxbryta-raises-questions-sends-Fulcrum-stock-higher)
previous post